ISPC
iSpecimen Inc
$
0.825
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.8371
Open
0.785
VWAP
0.76
Vol
2.07M
Mkt Cap
4.57M
Low
0.696399
Amount
1.57M
EV/EBITDA(TTM)
--
Total Shares
13.08M
EV
3.90M
EV/OCF(TTM)
--
P/S(TTM)
0.23
iSpecimen Inc. is a technology-driven company. The Company addresses a critical challenge, which focuses on connecting life science researchers who need human biofluids, tissues, and living cells (biospecimens) for their research. The Company’s iSpecimen Marketplace platform is designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. In addition to providing the technology platform to connect researchers and healthcare providers, the Company handles all marketing, sales, contracting, and compliance functions across both sides of the marketplace. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data and administrative, compliance and reporting.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
FY2024Q4
FY2024Q3
2.55M
+11.18%
--
--
2.98M
+15.61%
--
--
2.95M
+6.09%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for iSpecimen Inc. (ISPC) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -22.93%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-22.93%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for iSpecimen Inc (ISPC.O) is -0.05, compared to its 5-year average forward P/E of -14.68. For a more detailed relative valuation and DCF analysis to assess iSpecimen Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-14.68
Current PE
-0.05
Overvalued PE
42.39
Undervalued PE
-71.75
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.55
Current EV/EBITDA
-0.89
Overvalued EV/EBITDA
2.32
Undervalued EV/EBITDA
-5.42
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
1.52
Current PS
0.52
Overvalued PS
3.38
Undervalued PS
-0.33
Financials
Annual
Quarterly
FY2025Q2
YoY :
-75.10%
713.14K
Total Revenue
FY2025Q2
YoY :
-16.51%
-1.82M
Operating Profit
FY2025Q2
YoY :
-100.00%
N/A
Net Income after Tax
FY2025Q2
YoY :
-88.71%
-0.42
EPS - Diluted
FY2025Q2
YoY :
-100.00%
N/A
Free Cash Flow
FY2025Q2
YoY :
-24.96%
37.71
Gross Profit Margin - %
FY2025Q2
YoY :
+49.11%
-104.41
FCF Margin - %
FY2025Q2
YoY :
+99.39%
-146.85
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ISPC News & Events
Events Timeline
2025-07-24 (ET)
2025-07-24
08:41:24
iSpecimen prices 5.7M shares at 70c in underwritten public offering
2024-11-07 (ET)
2024-11-07
06:49:54
iSpecimen releases cancer biospecimen offering
2024-11-07
06:10:18
iSpecimen reports Q3 EPS ($2.10) vs ($4.66) last year
Sign Up For More Events
Sign Up For More Events
News
2.0
08-08BenzingaWhy Expedia Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
4.5
08-07SeekingAlphaiSpecimen plans $200M Solana-based digital asset treasury
8.5
08-04NewsfilteriSpecimen Inc. Announces Closing of Approximately $1.75 Million Private Placement Priced At-the-Market
Sign Up For More News
People Also Watch
ACON
Aclarion Inc
7.300
USD
+0.41%
NAOV
Nanovibronix Inc
5.395
USD
+7.26%
APVO
Aptevo Therapeutics Inc
1.980
USD
-4.35%
FRGT
Freight Technologies Inc
1.195
USD
-3.63%
SXTP
60 Degrees Pharmaceuticals Inc
1.260
USD
-3.08%
CYCC
Cyclacel Pharmaceuticals Inc
7.990
USD
-0.13%
BJDX
Bluejay Diagnostics Inc
1.390
USD
+3.73%
VLCN
Volcon Inc
0
USD
-15.80%
ADTX
Aditxt Inc
1.040
USD
+0.97%
FAQ
What is iSpecimen Inc (ISPC) stock price today?
The current price of ISPC is 0.8246 USD — it has increased 1.6 % in the last trading day.
What is iSpecimen Inc (ISPC)'s business?
What is the price predicton of ISPC Stock?
What is iSpecimen Inc (ISPC)'s revenue for the last quarter?
What is iSpecimen Inc (ISPC)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for iSpecimen Inc (ISPC)'s fundamentals?
How many employees does iSpecimen Inc (ISPC). have?